Sparta Biomedical Patents

Patent portfolio assigned to Sparta Biomedical (verified via public assignee records). Estimated patent count: 2. Synthetic-cartilage-on-titanium knee implant (Ormi/Galene) for knee osteoarthritis, FDA Breakthrough Device. Two patents granted (extending protection to 2040), described as the start of a growing portfolio so true count is likely higher. 'Customers' are first-in-human clinical trial sites, not commercial buyers (pre-market). Competitors are synthetic-cartilage knee-OA peers per Citeline.